First-line therapy with trastuzumab plus paclitaxel and carboplatin may be active in patients with HER-2 over-expressing metastatic breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1441, 2004-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab: A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

By Croom Katherine F.   Dhillon Sohita  

Drugs, Vol. 71, Iss. 16, 2011-11 ,pp. : 2213-2229

Adis International

Access to resources Recommend Favorite

Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer

By Keating Gillian M.  

Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. : 353-360

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

By  

Current Drug Targets, Vol. 14, Iss. 8, 2013-07 ,pp. : 889-898

Bentham Science Publishers

Access to resources Recommend Favorite

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite